Saglio, Giuseppe; Kim, Dong-Wook; Issaragrisil, Surapol; Le Coutre, Philipp; Etienne, Gabriel; Lobo, Clarisse; Pasquini, Ricardo; Clark, Richard E.; Hochhaus, Andreas; Hughes, Timothy P.; Gallagher, Neil; Hoenekopp, Albert; Dong, Mei; Haque, Ariful; Larson, Richard A.
(Massachusetts Medical Society, 2010-06)
BACKGROUND: Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia ...
